<DOC>
	<DOC>NCT02463071</DOC>
	<brief_summary>This study is a randomised, double-blind phase III long-term study to evaluate efficacy and safety of 12 weeks and 52 weeks of AZD0585 administration compared to placebo in patients with hyperlipidemia accompanied by hypertriglyceridemia .</brief_summary>
	<brief_title>AZD0585 Phase III Long-term Study in Japan</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Key Japanese men or women, â‰¥20 years of age. Subjects must meet all of the following criteria; 1. Fasting triglyceride level: average of Visit 2 and Visit 3 must be in the range 150 499 mg/dL 2. %TG change between Visit 2 and Visit 3 must be within 30% 3. %LDLC change between Visit 2 and Visit 3 must be within 25% Key Allergy or intolerance to omega3 fatty acids and omega3acid ethyl esters. Known lipoprotein lipase impairment or deficiency, or Apolipoprotein CII deficiency or familial dysbetalipoproteinemia. Current or history of pancreatitis. Type I diabetes mellitus, use of insulin, or haemoglobin A1c &gt;10% at Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>